IPSC
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Century Therapeutics Inc (IPSC) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (C+); its weakest is Growth (D). The rating has held at C for 70 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-08-05 | C+ (2.6) | D (1.3) | C+ (2.8) | C (2.4) | C- (1.9) | C (2.2) |
| 2026-08-04 | C+ (2.6) | D (1.3) | C+ (2.8) | C (2.4) | C- (1.9) | C (2.2) |
| 2026-08-03 | C+ (2.6) | C- (2.0) | C- (2.1) | C (2.4) | C- (2.0) | C (2.2) |
| 2026-08-02 | C+ (2.6) | C- (2.0) | C- (2.1) | C (2.4) | C- (1.9) | C (2.2) |
| 2025-03-31 | C+ (2.8) | C+ (2.5) | C (2.2) | C+ (2.7) | D+ (1.5) | C (2.3) |